Evolus, Inc. (NASDAQ:EOLS)
| Market Cap | $431.55M-4.8% |
| Revenue (ttm) | $325.47M+13.9% |
| Net Income | -$31.11M+46.9% |
| EPS | -$0.47+49.1% |
| Shares Out | 66.19M |
| PE Ratio | n/a |
| Forward PE | 19.76 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 813,646 |
| Open | $6.83 |
| Previous Close | $7.00 |
| Day's Range | $6.50 - $7.17 |
| 52-Week Range | $3.86 - $9.31 |
| Beta | 1.34 |
| Analysts | Buy |
| Price Target | $15.00(+130.06%) |
| Earnings Date | Mar 2, 2027 |
About EOLS
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating EOLS in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 2, 2027Earnings report
$EOLS stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in EOLS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by EOLS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
EOLS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
EOLS Revenue by Segment or Geography
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New EOLS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to EOLS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in EOLS
| IWMiShares Russell 2000 ETF | $10.86M |
| VTIVanguard Morningstar Total Stock Market ETF | $8.95M |
| VXFVanguard Extended Market ETF | $4.96M |
| IWOiShares Russell 2000 Growth ETF | $3.97M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $3.41M |
| VTWOVanguard Russell 2000 ETF | $2.57M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from EOLS’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 5Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| GLAM | Corgi ETF Trust I - Corgi Beauty, Skincare & Aesthetics ETF | 3.01% |
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 0.65% |
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.16% |
| IWC | iShares Micro-Cap ETF | 0.11% |
| PILL | Direxion Daily Pharmaceutical & Medical Bull 3X ETF | 0.10% |
| IHE | iShares U.S. Pharmaceuticals ETF | 0.09% |
| GSSC | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | 0.07% |
| VMO.TO | Vanguard Global Momentum Factor ETF | 0.05% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.03% |
| BIB | ProShares Ultra Nasdaq Biotechnology | 0.02% |
| VHT | Vanguard Health Care ETF | 0.01% |
Weight is the stock’s share of each fund’s holdings.
